Elotuzumab

• A study investigating the safety and efficacy of academically-produced CAR T cells compared with standard treatment for patients with multip… Pending
  2025-524876-43-00 Phase III 1 country Universitair Medisch Centrum Groningen
• C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL… Recruiting
  2023-507871-23-00 Phase III 16 countries Pfizer Inc.
• A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monot… Ended
  2023-506668-15-00 Phase III 13 countries AbbVie Deutschland GmbH & Co. KG
• A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-… Ended
  2022-502446-27-00 Phase III 13 countries Janssen - Cilag International
• A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Par… Ended
  2022-501396-62-00 Phase III 7 countries Regeneron Pharmaceuticals Inc.
• Clinical trial to compare selinexor pomalidomide dexamethasone combination with elotuzumab pomalidomide dexamethasone in multiple myeloma pa… Ended
  2024-518304-53-00 Phase III 6 countries European Myeloma Network B.V.
• CC-92480-MM-002 A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Prel… Ended
  2023-505219-19-00 Phase I/II 6 countries Celgene Corp.
• Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cel… Ended
  2024-515783-31-00 Phase III 2 countries Universitaetsklinikum Wuerzburg AöR
• Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma af… Ended
  2024-510590-14-00 Phase III 1 country University Medical Center Hamburg-Eppendorf
• Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab Ended
  2024-515490-10-00 Phase II 1 country Bristol Myers Squibb International Corporation
• A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with … Ended
  2023-509848-10-00 Phase III 7 countries Celgene Corp.
• A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Ref… Ended
  2023-509472-42-00 Phase III 14 countries Celgene International II S.a.r.l.

Showing 1–12 of 12 trials